Literature DB >> 11267947

Overexpression of CDK2 is a prognostic indicator of oral cancer progression.

M Mihara1, S Shintani, Y Nakahara, A Kiyota, Y Ueyama, T Matsumura, D T Wong.   

Abstract

Cyclins and cyclin-dependent kinases (CDKs) play key roles in cell cycle regulation, a process of which dysregulation can lead to uncontrolled cell growth and hence to cancer. We have already reported the alteration of CDK4 and cyclin D1 expression in oral cancer. In this study, we examined by immunohistochemistry the expression of CDK2, and cyclins A and E in 20 normal oral mucosa, 42 dysplastic epithelia, and 103 oral squamous cell carcinomas (SCCs). The expressions of CDK2, and cyclins A and E were not detected in the normal epithelium and significantly altered from epithelial dysplasia to SCC. While there were no significant correlations between the expression of cyclins A, E and the patients' survival, CDK2 expression was significantly correlated with lymph node involvement (P = 0.025), tumor differentiation (P = 0.032), mode of tumor invasion (P = 0.017), and shorter survival period (P = 0.0173). These results suggest that the elevated expression of CDK2 is a critical factor in oral cancer progression and can be used as a negative predictive marker of the patients' prognosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11267947      PMCID: PMC5926707          DOI: 10.1111/j.1349-7006.2001.tb01102.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  41 in total

1.  Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions.

Authors:  E Brambilla; S Gazzeri; D Moro; S Lantuejoul; S Veyrenc; C Brambilla
Journal:  Clin Cancer Res       Date:  1999-02       Impact factor: 12.531

2.  Immunohistochemical detection of sex steroid receptors, cyclins, and cyclin-dependent kinases in the normal and neoplastic squamous epithelia of the uterine cervix.

Authors:  M Kanai; T Shiozawa; L Xin; T Nikaido; S Fujii
Journal:  Cancer       Date:  1998-05-01       Impact factor: 6.860

3.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

4.  CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1.

Authors:  S Bates; L Bonetta; D MacAllan; D Parry; A Holder; C Dickson; G Peters
Journal:  Oncogene       Date:  1994-01       Impact factor: 9.867

5.  Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle.

Authors:  A Koff; A Giordano; D Desai; K Yamashita; J W Harper; S Elledge; T Nishimoto; D O Morgan; B R Franza; J M Roberts
Journal:  Science       Date:  1992-09-18       Impact factor: 47.728

6.  Heterogeneity of the proliferative fraction and cyclin D1/CCND1 gene amplification in head and neck squamous cell carcinoma.

Authors:  A K el-Naggar; K Steck; J G Batsakis
Journal:  Cytometry       Date:  1995-09-01

7.  Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner.

Authors:  E Lees; B Faha; V Dulic; S I Reed; E Harlow
Journal:  Genes Dev       Date:  1992-10       Impact factor: 11.361

8.  Deregulation of cyclin E in breast cancer.

Authors:  K Keyomarsi; D Conte; W Toyofuku; M P Fox
Journal:  Oncogene       Date:  1995-09-07       Impact factor: 9.867

9.  Cyclin E, a potential prognostic marker for breast cancer.

Authors:  K Keyomarsi; N O'Leary; G Molnar; E Lees; H J Fingert; A B Pardee
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

10.  Cyclin A is required at two points in the human cell cycle.

Authors:  M Pagano; R Pepperkok; F Verde; W Ansorge; G Draetta
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

View more
  17 in total

1.  Protein signatures for classification and prognosis of gastric cancer a signaling pathway-based approach.

Authors:  Daguang Wang; Fei Ye; Yabin Sun; Wei Li; Hongyi Liu; Jing Jiang; Yang Zhang; Chengkui Liu; Weihua Tong; Ling Gao; Yezhou Sun; Weijia Zhang; Terry Seetoe; Peng Lee; Jian Suo; David Y Zhang
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

Review 2.  Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region.

Authors:  Amanda Psyrri; George Fountzilas
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 3.  The CDK inhibitors in cancer research and therapy.

Authors:  Jonas Cicenas; Mindaugas Valius
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-30       Impact factor: 4.553

Review 4.  Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.

Authors:  Mitra Zabihi; Ramin Lotfi; Amir-Mohammad Yousefi; Davood Bashash
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-04       Impact factor: 4.553

Review 5.  Glycogen synthase kinase 3 beta: can it be a target for oral cancer.

Authors:  Rajakishore Mishra
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

6.  Knockdown of PFTK1 Inhibits the Migration of Glioma Cells.

Authors:  Shaochen Fan; Chengjin Zhao; Li Zhang; Shirong Dai; Jianbing Ren; Xiubing Zhang; Na Ban; Xiaojuan He; Lixiang Yang; Zhen Bao; Wenjuan Chen; Jie Sun; Yilu Gao; Tao Tao
Journal:  J Mol Neurosci       Date:  2015-08-04       Impact factor: 3.444

Review 7.  Can immunohistochemistry serve as an alternative to subjective histopathological diagnosis of oral epithelial dysplasia?

Authors:  Ahmad A Abdulmajeed; Camile S Farah
Journal:  Biomark Cancer       Date:  2013-10-10

8.  Dual control of Shuanghuang Shengbai granule on upstream and downstream signal modulators of CyclinD-CDK4/6 signaling pathway of cell cycle in Lewis-bearing mice with cyclophosphamide-induced myelosuppression.

Authors:  Xian Gu; Zhen-Ye Xu; Ling-Yu Zhu; Li-Fang Wang; Kai Li; Qiang Pei
Journal:  Onco Targets Ther       Date:  2013-03-22       Impact factor: 4.147

9.  Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma.

Authors:  H Miyagaki; M Yamasaki; H Miyata; T Takahashi; Y Kurokawa; K Nakajima; S Takiguchi; Y Fujiwara; H Ishii; F Tanaka; M Mori; Y Doki
Journal:  Br J Cancer       Date:  2012-02-14       Impact factor: 7.640

10.  Long non-coding RNA ELDR enhances oral cancer growth by promoting ILF3-cyclin E1 signaling.

Authors:  Subhayan Sur; Hiroshi Nakanishi; Robert Steele; Dapeng Zhang; Mark A Varvares; Ratna B Ray
Journal:  EMBO Rep       Date:  2020-10-12       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.